Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer

Study:

A Phase III Comparison of Biafine to Declared Institutional Preference for Radiation Induced Skin Toxicity in Patients Undergoing Radiation Therapy for Advanced Squamous Cell Carcinomas of the Head and Neck

Rationale:

Radiation therapy uses high-energy x-rays to damage tumor cells, but may cause skin irritation and inflammation. Biafine cream may be effective in lessening side effects caused by radiation therapy.

Purpose:

Randomized phase III trial to determine the effectiveness of Biafine cream in reducing side effects of radiation therapy in patients receiving treatment for head and neck cancer.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Head and Neck Cancer
Skin Reactions Secondary to Radiation Therapy		 Drug: Biafine cream
Procedure: quality-of-life assessment
Radiation: radiation therapy		 Phase 3

Verified by Radiation Therapy Oncology Group July, 2006

Sponsored by: Radiation Therapy Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00006481

Study Type: Interventional

Study Design: Supportive Care

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Elizabeth Elliott, MRT(T), MRT(R), CCRP., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.